Biognosys to Present at ALDA Fall 2022 Senior Executive Conference on Trends in Pharma Discovery & Manufacturing

Biognosys CEO Oliver Rinner, Ph.D., will discuss how proteomics is reshaping drug discovery in the Biopharma and CRO world

October 3, 2022. ZURICH and CAMBRIDGE, Mass. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are participating in the ALDA (Analytical, Life Science & Diagnostics Association) Fall 2022 Senior Executive Conference, “Trends in Pharma: The Latest Developments in Drug Discovery & Manufacturing”, taking place on October 2-4, 2022, in Zurich, Switzerland.

The ALDA Fall 2022 Conference features a rich program, including:

• Opening presentation by Peter Bofinger, Member of the German Council of Economic Experts
• Executive presentations and panels with Bayer, Biognosys, BioNTech, J.P. Morgan, McKinsey & Company, Mediar Therapeutics, Merck, MoonLake Immunotherapeutics, Nemesis Bioscience, and Solvias
• Closing Keynote Session with The Rt. Hon. Theresa May MP, Prime Minister of the United Kingdom (2016-2019), Current Member of Parliament

Biognosys’ presentation by CEO and co-founder Oliver Rinner, Ph.D., “How Proteomics is Reshaping Drug Discovery in the Biopharma and CRO World,” is scheduled on Monday, October 3.

ALDA is a non-profit industry trade association for global companies that develop and market products and services used in life science research, drug discovery, QA/QC and food testing, and clinical and molecular diagnostics. The Fall 2022 Conference is ALDA’s first European Senior Executive Conference for presidents, CEOs, COOs, and senior executives.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.

Media Contact

Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com

Download PDF Version (English)